Menu Close

COVID-19 Vaccine Updates & Member Contracts

 

Access Vaccines strives to support and inform our healthcare members to the best of our ability. We are closely monitoring the development of the COVID-19 vaccines and their availability for our members. As soon as we are able to provide COVID-19 vaccines to our members, we will support the best efficacy on the market and ensure the lowest prices available for our members. COVID-19 vaccine information and updates will be published here. In any case, do not hesitate to reach out to Access Vaccines for help in any vaccine or practice related issues that may arise during this time. You keep our communities healthy and safe; we are here for your support and guidance.

Enroll Here to Become One of our Covid 19 First Serve Mailing List

Access Vaccines is dedicated to providing our members with the most up-to-date programs that will allow you to access COVID-19 vaccines as they enter the private sector. Whether it be with GSK, Sanofi, or Pfizer, our membership programs can be customized to suit any practice & We will be ready to contact you as soon as more information is available on the timing of these vaccines.

Pfizer's COVID Vaccine For Younger Kids Meets FDA Bar With CDC Panel Next Week Being Key to Wide Rollout

October 29th, 2021 – Kids ages 5-11 in the United States are now eligible for a vaccination against COVID-19. On Friday afternoon, the FDA authorized the Pfizer-BioNTech mRNA vaccine, Comirnaty. The Pfizer shot is the only COVID jab with an FDA nod for those younger than 18.

The shot could be made available for kids soon. First it must pass muster with the CDC, which will conduct an advisory meeting next week.

The endorsement opens up the vaccine to a population of 28 million kids in the U.S. The Pfizer dosage for children is one-third the size of that for those 12 years and older. The second of the two-shot series is to be administered three weeks after the first.

Moderna, Johnson and Johnson COVID Booster's Nab FDA Nod's As Agency Backs "Mix and Match" Approach

The FDA has authorized a booster dose of Moderna’s COVID-19 vaccine, allowing it to play catch up with the Pfizer-BioNTech shot, which scored a booster approval last month.

The agency also blessed a second dose of the Johnson & Johnson vaccine. That nod applies to adults who have received one J&J shot two months prior.

“The currently available data suggest waning immunity in some populations of fully vaccinated people,” FDA acting commissioner Janet Woodcock told reporters on Wednesday night. “The availability of these authorized boosters is important for continued protection against COVID-19.”

Intrivo Launches At Home COVID Test That Delivers Results In 10 Minutes Via AI Powered App

October 22nd, 2021 – Just a few weeks after BD and Scanwell Health debuted their smartphone-based coronavirus diagnostic, Intrivo Diagnostics has begun rolling out its own rapid antigen test that connects to an artificial-intelligence-based app to guide users through the test-taking process, return their results and compile those findings into population-level databases.

Users begin by downloading the app through their iOS or Android app store or by scanning a QR code on the outside of the On/Go test kit’s box. The On/Go app will then guide them through the process of collecting a nasal swab, mixing it with the testing solution and applying the solution to a testing cartridge. Once completed, users snap a photo of the cartridge, and the app generates their results and any subsequent guidance within about 10 minutes.

The app saves the results of all On/Go tests taken by an individual, as well as their vaccine records, allowing it to be used as a secure digital COVID passport. If the tests are distributed by a school, workplace, venue or other organization, their results are compiled by On/Go’s AI platform to help track and mitigate outbreaks as they crop up.

 

US F.D.A. Changes COVID-19 Authorizations

October 21st, 2021 – The U.S. Food and Drug Administration (FDA) announced various actions to expand the use of COVID-19 vaccines in eligible populations.

The FDA amended the emergency use authorizations (EUA) for FDA Authorized or Approved COVID-19 vaccines to allow for the heterologous (“mix and match”) use of a single booster dose.

And the FDA confirmed the increased risks of inflammatory heart conditions for younger men following mRNA vaccination.

The highlight changes are as follows:

  • The use of a single booster dose of the Moderna COVID-19 Vaccine (SpikeVax) that may be administered at least six months after completion of the primary series to individuals 65 years of age and older; 18 through 64 years of age at high risk of severe COVID-19; 18 through 64 years of age with frequent institutional or occupational exposure to the SARS-CoV-2 betacoronavirus.

  • Use of a single booster dose of the Janssen (Johnson and Johnson) COVID-19 Vaccine may be administered at least two months after completion of the single-dose primary regimen to individuals 18 years of age and older.

  • The use of each of the available COVID-19 vaccines as a heterologous (or “mix and match”) booster dose in eligible individuals following primary vaccination with a different available COVID-19 vaccine.

  • The FDA clarified that a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) may be administered at least six months after completing the primary series to individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.

Johnson & Johnson COVID-19 Vax Recipients See Stronger Results with Moderna, Pfizer Boosters, Study Says, But Notes Comparison Limitations

October 14th, 2021 – A study released on Wednesday ahead of an FDA advisory committee meeting on COVID-19 booster shots notes that Johnson & Johnson vaccine recipients may be better off receiving a second shot from Moderna or Pfizer-BioNTech.

The preprint data may factor into the ongoing FDA advisory committee meeting over today and Friday to consider whether to recommend additional doses as boosters for J&J’s and Moderna’s authorized vaccines.

The study, conducted by the NIH, has its limitations as it relies on antibody counts. Experts have yet to be able to equate immune response to actual protection.

Amid Heated Debate FDA Hands Limited Nod to Pfizer For COVID-19 Boosters

September 23rd, 2021 – The FDA’s limited emergency use authorization of a third dose of Pfizer’s COVID-19 vaccine stopped short of the more sweeping approval of the shot the company was hoping for, which was no surprise given that an advisory board voted 16-2 against making boosters available to all adults. Now, the company is facing a booster rollout amid heated debate on the necessity of additional shots and revelations that two top vaccine experts will depart the FDA before the end of the year.

The FDA ruled yesterday that booster shots of Pfizer’s Comirnaty vaccine should be made available to people age 65 and older, as well as adults with conditions that make them more susceptible to serious complications of the virus or who have jobs that put them at a higher risk of exposure. The Centers for Disease Control and Prevention plans to meet today to refine the booster approval, recommending who can get the shots and when they’ll become eligible.